[Articles] Dynamic choice HIV prevention with long-acting injectable cabotegravir pre-exposure prophylaxis in east, central, southern, and west Africa: a cost-effectiveness modelling analysis

Offering structured PrEP and PEP choice including long-acting cabotegravir and enabling risk-informed use could reduce HIV incidence by a third over 10 years. If projected generic production costs of long-acting cabotegravir can be realised, it is likely to be cost-effective across multiple settings in east, central, southern, and west Africa.